About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 569438, 6 pages
http://dx.doi.org/10.1155/2013/569438
Research Article

Transcriptomic Profiling of the Four Adenosine Receptors in Human Leukocytes of Heart Failure Patients

1Laboratory of Cardiovascular Biochemistry, CNR Institute of Clinical Physiology, Via Giuseppe Moruzzi 1, 56124 Pisa, Italy
2CNR Institute of Clinical Physiology, 20162 Milan, Italy
3Cardiovascular Department, Niguarda Ca' Granda Hospital, 20162 Milan, Italy

Received 18 April 2013; Revised 17 May 2013; Accepted 22 May 2013

Academic Editor: Ahmed Abdel-Latif

Copyright © 2013 Manuela Cabiati et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

In this study the transcriptomic profiling of adenosine receptors (ARs) in human leukocytes of heart failure (HF) patients as a function of clinical severity, assessing the possible changes with respect to healthy subjects ( ), was evaluated. Total RNA was extracted from leukocytes of ( ) and of HF patients (NYHA I-II ; NYHA III-IV ) with a PAXgene Blood RNA Kit. An increase as a function of clinical severity was observed in each AR (A1R: , NYHA , NYHA ,    versus NYHA III-IV, NYHA I-II versus NYHA III-IV; A2aR: , NYHA , NYHA ,    versus NYHA III-IV, NYHA I-II versus NYHA III-IV; A2bR: , NYHA , NYHA , : NYHA I-II versus NYHA III-IV; A3R: , NYHA , NYHA ,    versus NYHA III-IV and NYHA I-II versus NYHA III-IV, resp.). The mRNA expression of the ectonucleoside triphosphate diphosphohydrolase (CD39) and the ecto-5′-nucleotidase (CD73) were also evaluated. They resulted up-regulated. These findings show that components of adenosine metabolism and signalling are altered to promote adenosine production and signalling in HF patients. Thus, HF may benefit from adenosine-based drug therapy after confirmation by clinical trials.